The University of Texas Medical School at Houston
gray bar graphic
  UTHSC-H     People Directory     Webmail     Calendar      A-Z
Search
BMB Home | Meet the Faculty | BMB Newsletter | BMB Links | Contact BMB
 
 

Dr. Rick A. Wetsel, Professor

Dr. Rick A. WetselDepartment of Autoimmune Disease Research Center
Program in Biochemistry and Molecular Biology

UT Houston Health Science Center
Institute of Molecular Medicine
1825 Pressler Street - Houston, Texas 77030
(713) 500-2412 fax: (713) 500-2420
email
: Rick. A. Wetsel@uth.tmc.edu

Ph.D, UT Health Science Center at San Antonio
Postdoctoral Fellow, Scripps Research Institute
Career Research Development Award, National Institutes of Health

 



molecular genetics, structure, & transgenic studies of chemoattractant receptors

My laboratory's research interests are directed at understanding the molecular events involved in mediating the inflammatory and immune response in both normal and pathological conditions. Much of our work is focused on studies of the complement anaphylatoxin receptors. These receptors have been implicated in playing major roles in numerous diseases, including rheumatoid arthritis, asthma, psoriasis, lupus, and atherosclerosis.

To examine the requisite role of the anaphylatoxin receptors in these and other diseases, we have generated several "knock-out" mice in which the genes encoding these receptors and their ligands have been selectively inactivat-ed by homologous recombination methods. These mice have already been employed in studies of a mouse model of asthma which has revealed that the C3a anaphylatoxin peptide may be a major contributor in the recruitment of eosinophils into the lung airways during the early stages of asthma.

The overall goal of our research program for the next five years is to increase our understanding of the specific and overall roles that complement anaphylatoxin peptides and their receptors play in inflammation and immunity. These studies will be carried out using the complement "knock-out" mice generated in our laboratory. We will determine the cells in peripheral blood and tissues that express the receptors in vivo, and determine biological functions mediated by these cells after ligand stimulation. In addition, we will determine the overall effect of these receptors in pul-monary and skin diseases as well as in bacterial sepsis. "Knock-out" animals will also be generated in which genes that are thought to control inactivation of the complement anaphylatoxin peptides will be disrupted. This will allow us to examine in vivo the molecular regulation of these potent mediators of inflammation.

Figure 1


Selected References

Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006 12:682-687.

Drouin SM, Sinha M, Sfyroera G, Lambris JD, Wetsel RA. A protective role for the fifth complement component (C5) in allergic airway disease. Am J Respir Crit Care Med. 2006 173:852-857.

Mueller-Ortiz SL, Drouin SM, Wetsel RA. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun. 2004 72:2899-2906

Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol. 2002 169:5926-5933.